The central research theme of the group is the study of structure-function relationships of signaling enzymes with an emphasis on protein tyrosine phosphatases. We aim to contribute to the understanding of how their structural characteristics are correlated with specific signaling functions. To this purpose we analyze each signaling enzyme which we are investigating from multiple directions:
The combination of results thus obtained in this way is further used in shedding light on the signaling mechanism and on the overall functional role of the given enzyme.
The group has good experience and is currently involved in production, isolation and purification of recombinant proteins, expressed both in prokaryotic and eukaryotic systems. The research activity of the group is performed by tools of molecular biology (recombinant DNA, site-directed mutagenesis, (RT)-PCR, Western blotting, immunoprecipitation, etc.), spectroscopic analysis (UV-VIS and fluorescence spectrophotometry), cellular biology, protein crystallization and enzyme kinetic analysis.
The decline of cognitive capacity is one of the most debilitating features of neurodegenerative diseases. To a great extent, this is due to changes in the molecular composition of postsynaptic membranes which in turn leads to reduced synaptic plasticity. Synaptic function depends on synaptic plasticity which can either potentiate or depress information transfer. As a rule, high-frequency stimulation potentiates synaptic activity leading to long-term potentiation (LTP) while low-frequency stimulation depresses synaptic activity leading to long-term depression (LTD). Long term changes in synaptic functions can be induced by activation of NMDA receptors which modify synaptic strength through regulating the number of postsynaptic AMPA receptors (AMPAR). NMDAR activation leads to Ca2+ influx through the receptor coupled ion channel which can initiate either LTP or LTD, depending on the spatiotemporal activation profile. Cognitive impairment and learning ability of the brain is directly linked to synaptic plasticity as measured in LTP changes in animal models of brain diseases.
AMPARs are glutamate-activated ion channels which mediate the fast excitatory ion current underlying information transmission in the brain. An increase in the number of postsynaptic AMPARs leads to increased synaptic strength during LTP, while a decrease in postsynaptic AMPAR number produces LTD. Increased number of AMPAR during LTP can be mediated by both exocytosis of AMPARs and/or lateral diffusion of AMPARs from the peri-synaptic membrane to the synapse. Conversely, LTD leads to AMPAR diffusion away from the synapse and receptor endocytosis.
Post-translational modifications of AMPAR cytoplasmic region like tyrosine phosphorylation were proved to play important role in receptor trafficking and other processes so that a specific phosphorylation pattern of this receptor might be associated with a physiological or pathological state. The main idea of this project is to modulate the phosphorylation state of AMPA receptors in such a manner to favor a physiological functionality of the receptor. Eventually, we aim at identifying lead compounds with potential cognitive enhancement effect.
Eyes absent (eya) proteins are members of a regulatory network of evolutionary conserved transcription factors and cofactors, termed retinal determination gene network (RDGN) in Drosophila, along with twin of eyeless (toy), eyeless (ey), sine oculis (so) and dachshund (dac). From insects to humans, there are correspondent gene families - Pax (for toy and ey), Six (for so), Eya (for eya) and Dach (for dac) - referred to as the PSEDN (Pax-Six-Eya-Dach) network. This network holds important roles in the development and homeostasis of various tissues and organs - eyes, kidneys, nervous system, ears, muscles - as well as in the context of limb formation, gonadogenesis and neurogenesis. Loss of function mutations in the Eyes absent genes can lead to several congenital syndromes, for example cardiofacial syndrome, bronchio-oto-renal syndrome, oto-facio-cervical syndrome, congenital cataract, late onset of deafness. On the other hand, overexpression of Eyes absent has been detected in diverse types of cancers like epithelial ovarian cancer, Wilms’ tumors, lung adenocarcinoma, colorectal cancer, colon cancer, esophageal adenocarcinoma.
Post-translational modifications of EYA proteins may influence their implication in physiological and pathological events. Recently, we have demonstrated and reported that Src kinase phosphorylates human EYA1 and EYA3 and their nuclear and cytoskeletal localization are controlled by Src phosphorylation. In the same time, we have found that EYA1 and EYA3 are capable of autodephosphorylation. We have also shown that Src kinase has phosphorylation sites in both N-terminal and C-terminal domains of EYA3 protein. This data brings into discussion the implication of tyrosine phosphorylation in regulating the physiological activities of eyes absent proteins and potential interacting partners in mammalian cells. Thus, in this project we perform a detailed mass spectrometric analysis of human EYA3 phosphorylation by protein tyrosine kinase Src and analyze whether the phosphorylation sites can be autodephosphorylated. In terms of our future objectives we plan to identify the physiological impact of the phosphorylation of the detected tyrosine residues.
Protein tyrosine phosphorylation represents only a tiny fraction (~ 0.05%) from the total protein phosphorylation of eukaryotic cells. However, it has emerged as a major regulatory mechanism in signal transduction. Many essential cellular processes such as cell growth, differentiation, adhesion and migration, cell cycle control, gene transcription, angiogenesis as well as regulation of ion channels in nerve transmission are modulated by tyrosine phosphorylation. The perturbation of the balance between tyrosine phosphorylation and dephosphorylation has severe pathological consequences leading to numerous human diseases including cancer, diabetes, immune and neuronal diseases. Therefore, maintaining of the adequate level of protein tyrosine phosphorylation in eukaryotic cells is a process which is tightly regulated by the concerted action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs).
At present, one of the most problematic drawbacks in understanding the involvement of PTPs in regulation of signaling processes remains the poor knowledge of their physiological substrates. Thus, for relatively few cases tyrosine-phosphorylated proteins (pY-proteins) having essential roles in different biological processes, the specific dephosphorylating PTPs are known. Identification of PTPs able to dephosphorylate physiologically important pY residues not only would help to enlighten the complex map of tyrosine phosphorylation-mediated pathways but also would offer new tools for diagnostic and therapy. Thus, the aim of the present project is to develop a new technique for direct identification of PTP(s) that specifically dephosphorylate pY-proteins and to apply this novel procedure to the identification of PTPs which dephosphorylate given tyrosine-phosphotylated proteins of high interest for cell signaling.
G-protein coupled receptors (GPCRs) are the largest family of plasma membrane proteins in mammals encoded by 800 genes in humans and more than 1000 in rodents. A large number of them are olfactory receptors whereas the rest respond to a diverse spectrum of ligands regulating a plethora of physiological processes. Although intensive research performed by pharma industry and academia led to development of drugs acting on GPCRs, the human genome encodes more than 120 receptor members with unknown ligands and physiological functions, known as “orphan GPCRs” (oGPCRs).
By using a combination of reverse- and forward- pharmacology, complemented by advanced mouse genetic models we aim to understand the biological roles of oGPCRs highly expressed mainly in the nervous system, adipose tissue and pancreatic cells.
Critical for successful identification of the biological roles of oGPCRs are the core technologies we are currently employing and further expanding. They include, but are not limited to:
Mouse genetics. To understand the biological role of selected oGPCRs we are currently developing advances mouse genetics in collaboration with Max Planck Institute for Heart and Lung Research. These models include generation of mice lacking the receptor gene, in tissue- specific and -conditional manner. Also, to obtain valuable information regarding receptor expression, we plan to generate genetic reporter mouse models, in which fluorescent proteins are expressed under the endogenous promoter of the oGPCR.
Transient receptor potential melastatin (TRPM) channels are a subfamily of transient receptor potential (TRP) family of ion channels with a high genetic and functional diversity. TRPM8 is a polymodal receptor-channel expressed in primary afferent sensory neurons and also in non-neuronal tissue. It is activated by cooling and plant-derived compounds (menthol, eucalyptol, camphor) and modulated in a voltage channel-dependent manner. Its main sensory role is to transduce innocuous cooling, being widely accepted to be a major sensor of environmental cold temperature. It is also involved in a variety of pathological pain states, including neuropathic and inflammatory hypersensitivity to cold. Recent reports have shown that TRPM8 is necessary to the initiation and progression of tumors and the abnormal expression of TRPM8 was found in various tumor forms. Therefore, TRPM8 is considered one of the most promising novel therapeutic targets in cancer therapy. The activity of TRPM8 is regulated by various intracellular messenger molecules and signaling pathways. Thus, it is reasonable to assume that post-translational modifications could play a significant role in regulation of TRPM8 activity.
Our project intends to investigate the effect of post-translational modifications of TRPM8 on channel function, to identify the molecular determinants involved in this process and to evaluate the structural impact of this post-translational modification.
Ionescu AE, Mentel M, Munteanu CVA, Sima LE, Martin EC, Necula-Petrareanu G, Szedlacsek SE.
Int J Mol Sci. 2019 Dec 13;20(24). pii: E6307. doi: 10.3390/ijms20246307.
Manolache A, Selescu T, Maier GL, Mentel M, Ionescu AE, Neacsu C, Babes A, Szedlacsek SE.
J Cell Physiol. 2019 Nov 14. doi: 10.1002/jcp.29397. [Epub ahead of print]
Zimta AA, Schitcu V, Gurzau E, Stavaru C, Manda G, Szedlacsek S, Berindan-Neagoe I. Environ Res. 2019
Nov;178:108700. doi: 10.1016/j. Review.
Scheidig AJ, Horvath D, Szedlacsek SE. J Struct Biol. 2019 Jul 1;207(1):85-102.
Rosca AM, Mitroi DN, Cismasiu V, Badea R, Necula-Petrareanu G, Preda MB, Niculite C, Tutuianu R, Szedlacsek SE, Burlacu A. J.Cell.Mol.Med., 2018, 22(10), 4700-4708
Mentel M, Ionescu AE, Puscalau-Girtu I, Helm MS, Badea RA, Rizzoli SO, Szedlacsek SE. Sci Rep. 2018 Feb 13;8(1):2910.
Tunaru S, Bonnavion R, Brandenburger I, Preussner J, Thomas D, Scholich K, Offermanns S. Nat Commun. 2018 Jan 12;9(1):177.
Schmitz K, Brunkhorst R, de Bruin N, Mayer CA, Häussler A, Ferreiros N, Schiffmann S, Parnham MJ, Tunaru S, Chun J, Offermanns S, Foerch C, Scholich K, Vogt J, Wicker S, Lötsch J, Geisslinger G, Tegeder I. Acta Neuropathol Commun. 2017 Jun 2;5(1):42.
Hohmann SW, Angioni C, Tunaru S, Lee S, Woolf CJ, Offermanns S, Geisslinger G, Scholich K, Sisignano M. Sci Rep. 2017 Mar 27;7(1):446.
Zinn S, Sisignano M, Kern K, Pierre S, Tunaru S, Jordan H, Suo J, Treutlein EM, Angioni C, Ferreiros N, Leffler A, DeBruin N, Offermanns S, Geisslinger G, Scholich K. J Biol Chem. 2017 Apr 14;292(15):6123-6134.
Mentel M, Badea RA, Necula-Petrareanu G, Mallikarjuna ST, Ionescu AE, Szedlacsek SE. Methods Mol Biol. 2016;1447:39-66.
Tunaru S, Chennupati R, Nüsing RM, Offermanns S. PLoS One. 2016 Sep 23;11(9):e0163633.
Tang C, Ahmed K, Gille A, Lu S, Gröne HJ, Tunaru S, Offermanns S. Nat Med. 2015 Feb;21(2):173-7.
Petrareanu G, Balasu MC, Vacaru AM, Munteanu CV, Ionescu AE, Matei I, Szedlacsek SE. Appl Microbiol Biotechnol. 2014 Sep;98(18):7855-67.
Preuss B, Tunaru S, Henes J, Offermanns S, Klein R. Clin Exp Immunol. 2014 Jul;177(1):179-89.
Conzelmann M, Williams EA, Tunaru S, Randel N, Shahidi R, Asadulina A, Berger J, Offermanns S, Jékely G. Proc Natl Acad Sci U S A. 2013 May 14;110(20):8224-9.
Böhmer F, Szedlacsek S, Tabernero L, Ostman A, den Hertog J. FEBS J. 2013 Jan;280(2):413-31.
Tunaru S, Althoff TF, Nüsing RM, Diener M, Offermanns S. Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9179-84.
Synthesis of the ancestral PTP catalytic domain and its characterization both in vitro and in vivo.
Molecular modeling of a set of peptides that can disrupt the GluA2-Cterm complex with STEP (Complex A) or BRAG2 (ComplexB).
The project is agreed as a joint collaboration among IBAR and ATOMKI, UD and IFIN-HH is a cost free participant. There are two main directions envisaged by the proposed project: receptors mapping and therapy, using an affibody against HER2 receptor, combined with an adequate radioisotope. In this respect, the specific objectives are: a) expression and purification of affibodies; b) establish labeling procedures; c) ex vivo and/or in vivo testing of optimal compounds.
PTPs are proteins with enzymatic properties and a range of cell and tissue functions.